宏信证券：每日信息速递-20240828

Key Points Summary Economic and Financial Developments - The People's Bank of China and seven other departments have issued guidelines to enhance financial support for the green, low-carbon, and high-quality development of the Yangtze River Economic Belt, emphasizing ecological priority and green development [2][3] - From January to July 2024, the total amount of family mutual aid from employee medical insurance accounts exceeded 22.738 billion yuan, with 191 million person-times participating in the mutual aid [2][3] - In the first seven months of 2024, the total profit of industrial enterprises above designated size in China increased by 3.6% year-on-year, reaching 40,991.7 billion yuan [4][5] Industry-Specific Insights - The profits of state-owned enterprises in the first seven months of 2024 totaled 25,701.5 billion yuan, a decrease of 2.0% year-on-year, while their total operating revenue was 472,872.7 billion yuan, an increase of 1.6% [5][6] - The lottery sales in China for 2023 reached 579.696 billion yuan, with welfare lottery sales accounting for 19.444 billion yuan and sports lottery sales for 38.525 billion yuan [6][7] - The Ministry of Agriculture and Rural Affairs emphasized the importance of supporting dairy and beef production as a key aspect of financial support for agriculture [12] Corporate Announcements - Aojing Medical announced that its polyester/collagen-based artificial bone repair material has received registration acceptance from the National Medical Products Administration [15] - Huadong Medicine's subsidiary received FDA approval for its sodium fondaparinux injection, a heparin-class anticoagulant [16] - Saiseng Pharmaceutical plans to invest up to 1.1 billion yuan of idle funds in financial products to enhance capital efficiency [17] - China Shipbuilding Industry Corporation signed a contract for the construction of six 150,000 cubic meter ethane transport vessels [18] - Kelong Pharmaceutical's subsidiary received registration approval for its bupivacaine liposome injection, marking it as the second company in China to obtain such approval [20]